Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02413554|
Recruitment Status : Completed
First Posted : April 10, 2015
Last Update Posted : April 10, 2015
|Condition or disease||Intervention/treatment||Phase|
|Delirium||Drug: Rivastigmine patch||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia.|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||April 2015|
Experimental: Patch applied patients
The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.
Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation.
Drug: Rivastigmine patch
acetylcholine esterase inhibitor
Other Name: exelon patch
No Intervention: Patch non-applied patients
The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
- the number of participants with delirium [ Time Frame: up to 7th days ]investigators evaluated the delirium frequency in rivastigmine applied participants comparing with non-applied participants.
- delirium severity using delirium rating scale [ Time Frame: up to 7th days ]to compare the severity of delirium in rivastigmine patch applied participants with non-applied
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02413554
|Principal Investigator:||Young Chul Youn, MD, PhD||Dept of Neurology, Chung-Ang University Hospital|